Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Investor Presentation (February 2023)
17 slides from Atomo Diagnostics's investor presentation, Feb 23, 2023
Slide 1: H1 FY23 Results Presentation
Atomo Diagnostics Limited Authorized by John Kelly, Managing Director Level 1, 3-5 George Street Leichhardt NSW 2040 Australia H1 FY23 Results Presentation FEBRUARY 2023 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 2: Introduction to Atomo
INTRODUCTION TO ATOMO Atomo Diagnostics Limited (ASX: AT1) is an innovative medical device diagnostics company supplying unique, integrated rapid diagnostic test (RDT) devices and finished point-of-care rapid tests to global partners Atomo develops, manufactures and sells innovative rapid tests and
Slide 3: Atomo's Value Add and Investment Case
ATOMO’S VALUE ADD AND INVESTMENT CASE • Market Leading Integrated Rapid Diagnostic Test (RDT) Devices – Atomo is establishing itself as a leader in the development of innovative integrated rapid test devices. The next stage of business growth presents an opportunity to create a global leader in th
Slide 4: H1 FY23 - Profit & Loss
H1 FY23 - PROFIT & LOSS AUD H1 FY23($m) H1 FY22($m) (%) • Total customer revenue of $1.36m is lower than the prior Revenue 1.36 5.34 (75%) comparable period as COVID-19 business fell away Cost of sales (1.12) (3.58) • When revenue is normalised for COVID-19 sales, there is an Gross Profit 0.24 1.76
Slide 5: H1 FY23 - Balance Sheet
H1 FY23 - BALANCE SHEET H1 FY23 FY22 • Cash balance of $10.16m at 31 December 22 and debt free AUD ($m) ($m) • Inventory balance reduced following the provision relating Cash and cash equivalents 10.16 12.97 to COVID-19 professional use rapid antigen tests Trade and other receivables 1.54 2.68 • Cap
Slide 6: H1 FY23 - Cash Flow
H1 FY23 - CASH FLOW • Cash receipts of $1.83m from customers • A further $1.21m received from the R&D tax rebate and EMDG programmes • Cash payments for stock of $676k • Opex, capex and R&D activities in line with expectations • Total Cash outflow for the H1 period was less than $2.8M ATOMO DIAGNOST
Slide 7: Diagnostics Landscape and Trends
DIAGNOSTICS LANDSCAPE AND TRENDS HIV POINT OF CARE EXPERIENCING DISRUPTION & RAPID GROWTH Rapid testing – growth and increased acceptance Point of care – driving investment • Growing demand for reliable, rapid, decentralised diagnostic testing for • Low-cost, easy to use point of care diagnostics wi
Slide 8: Strategic Business Focus
STRATEGIC BUSINESS FOCUS CORE CAPABILITIES Innovation, Device development, Usability, Regulatory Approval & Commercialisation BUSINESSES Point of Care Tests POC Technology • HIV & COVID-19 1 • Blood test devices • hCG pregnancy 2 • Swab test devices • Ferritin 3 • Custom Reagent Blisters • Vitamin D
Slide 9: Unique Core Capabilities
UNIQUE CORE CAPABILITIES IP Intensive Less IP Intensive More customer focused Atomo DNA Core Functionality Devices Finished Products Market Access Point-of-Care Self Testing • Blood collection • Galileo • HIV • Supply Agreements for • Saliva & swab collection • Pascal • COVID Finished Products • Des
Slide 10: Best in Class Usability
BEST IN CLASS USABILITY UNMATCHED PERFORMANCE FOR BLOOD TESTING An independent usability study with users performing a rapid blood test for the first time using an Atomo Pascal test and a CE Marked Self-Test multi-component rapid test kit Outstanding Pascal Performance: 1. Greater than 90% reduction
Slide 11: Global Operations & Business Opportunity
GLOBAL OPERATIONS & BUSINESS OPPORTUNITY EUROPE • Atomo HIV ST and HIV Professional use, blood-based pregnancy tests and FebriDx all CE marked NORTH AMERICA • Strategic partnership with NG Biotech ASIA for pregnancy testing • Rapidly growing at-home test channels post COVID • Cassette moulding and a
Slide 12: Key Priorities
KEY PRIORITIES PRIORITIES FOR THE RAPID TEST BUSINESS Growing the HIV business and delivering significant HIV sales growth over the next three years ; • increased sales mix from developed markets where margins are materially better • near term launch of a professional test through a new European dis
Slide 13: Earlier Detection of Pregnancy
EARLIER DETECTION OF PREGNANCY • Intended use: Detection of early pregnancy in human whole blood samples • AtomoRapid hCG is an immunochromatographic assay for the qualitative detection of hCG in human capillary whole blood collected from the fingertip with a sensitivity of 10lU/ml • The test includ
Slide 14: Monitoring for Iron Sufficiency
MONITORING FOR IRON SUFFICIENCY INTENDED USE: The Ferritin rapid test is a rapid qualitative test in the Pascal Platform to determine if the level of ferritin in whole blood is above or below a certain cut-off (30ng/ml). The test would be suitable as a routine screening test that would be performed
Slide 15: Key Priorities
KEY PRIORITIES PRIORITIES FOR THE POINT-OF-CARE TECHNOLOGY BUSINESS Continuing to build out a customer base of rapid test manufacturers that choose Atomo’s blood and swab test devices to commercialise their rapid tests Securing ‘reseller’ commercial agreements in the US and Europe with lateral flow
Slide 16: Atomo's Swab Test Solution
ATOMO’S SWAB TEST SOLUTION TARGETING LATERAL FLOW, MOLECULAR AND MICRO-FLUIDIC MARKETS Key Takeaways Key Takeaways • In benchtop internal studies, the Atomo Swab Platform shows approximately 50% higher test line intensity than rapid test 1 and There are several functionalities delivering the approxi
Slide 17: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on other written or oral communications transmitted or otherwise made available to the information available as at the date of this presentation. The information in this recipient in connection with the oppor
Atomo Diagnostics — Investor Presentation (February 2023) on 6ix